Content provided by Lonza Small Molecules | 13-Nov-2023
| White Paper
Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract
Content provided by Lonza | 12-Oct-2023
| White Paper
Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...
Content provided by Lonza Small Molecules | 09-Oct-2023
| White Paper
Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...